• Home
  • About
  • Products
    • HylaJel
    • HylaPure
    • Other Products
  • Investor Relations
  • News
  • Careers
  • Contact Us
Log in
FDA Approves 1st IND of its Kind for Allogenic Exosomal Treatment

FDA Approves 1st IND of its Kind for Allogenic Exosomal Treatment

by admin | Jan 9, 2023 | FDA, Stem Cells

LIBERTY, Mo., Oct. 18, 2022 /PRNewswire/ — Vitti Labs, an AATB Accredited Tissue Bank focused on life science research, development, and manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved their Investigational New Drug...

Links

HylaJel
HylaPure
Other Products
Investor Relations

 

  • Follow
  • Follow
  • Follow

Company

About
Contact
News
Careers
Distributor Login

Sign up for Updates, Promotions, and More.

Success!

Submit